Boston Scientific (BSX) director receives $215,000 restricted stock award

Rhea-AI Filing Summary

Mega Jessica L reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Jessica L. Mega received an annual equity award of 3,800 shares of Common Stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. The footnote explains the grant reflects a value of $215,000 divided by the closing price of the common stock on the grant date. Following this compensation-related award, she directly holds 12,035 shares of Boston Scientific common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mega Jessica L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,800	$0.00	--

Holdings After Transaction: Common Stock — 12,035 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 3,800 shares Award value: $215,000 Post-transaction holdings: 12,035 shares

3 metrics

Restricted stock grant 3,800 shares Annual equity award of Common Stock

Award value $215,000 Equity award value divided by closing price on grant date

Post-transaction holdings 12,035 shares Common Stock directly held after grant

Key Terms

restricted stock, annual equity award, closing price

3 terms

restricted stock financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual equity award financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

closing price financial

"Reflects a value of $215,000 divided by the closing price of common stock on the date of grant"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mega Jessica L

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		3,800	A	$0.0000	12,035	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Boston Scientific (BSX) director Jessica Mega report on this Form 4?

Jessica L. Mega reported receiving an annual equity award of 3,800 shares of Boston Scientific Common Stock. These shares are restricted stock granted as director compensation and will vest in full at the next annual meeting of stockholders, according to the Form 4 footnote.

Is the Boston Scientific (BSX) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a stock grant, not an open-market purchase. Jessica L. Mega received 3,800 restricted shares as an annual equity award, with no cash price per share, reflecting standard director compensation rather than a discretionary market transaction.

How is the value of Jessica Mega’s Boston Scientific (BSX) equity award determined?

The equity award value is set at $215,000, divided by the closing price of Boston Scientific common stock on the grant date. This calculation determines the 3,800 restricted shares granted, aligning the award’s dollar value with the company’s market price that day.

When do Jessica Mega’s restricted Boston Scientific (BSX) shares vest?

The restricted stock granted to Jessica L. Mega vests in full at the next annual meeting of stockholders. Until vesting, the 3,800-share award remains subject to the restricted stock terms described in the Form 4 footnote and applicable company equity plans.

How many Boston Scientific (BSX) shares does Jessica Mega hold after this Form 4 transaction?

After the equity award, Jessica L. Mega directly holds 12,035 shares of Boston Scientific common stock. This total includes the 3,800 restricted shares granted as her annual equity award, as reported in the Form 4 transaction details.